Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

566 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
Chen SL, Ye F, Zhang JJ, Zou JJ, Qian XS, Li F, Yang S, Ge Z, Shan SJ, Li XB, Xu T, Kan J, Lin L, Han YL. Chen SL, et al. Among authors: han yl. Cardiovasc Ther. 2013 Aug;31(4):193-200. doi: 10.1111/j.1755-5922.2012.00319.x. Cardiovasc Ther. 2013. PMID: 22954234 Free article. Clinical Trial.
Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, Jiang T, Li Z, Zhang H, Li H, Qiu J, Liu Y, Li Y, Chen X, Gao R; CREATE (Multi-Center Registry of Excel Biodegradable Polymer Drug-Eluting Stents) Investigators. Han Y, et al. JACC Cardiovasc Interv. 2009 Apr;2(4):303-9. doi: 10.1016/j.jcin.2008.12.013. JACC Cardiovasc Interv. 2009. PMID: 19463441 Free article. Clinical Trial.
Sustained clinical safety and efficacy of a biodegradable-polymer coated sirolimus-eluting stent in "real-world" practice: three-year outcomes of the CREATE (Multi-Center Registry of EXCEL Biodegradable Polymer Drug Eluting Stents) study.
Han Y, Jing Q, Li Y, Yang L, Liu H, Shang X, Jiang T, Li Z, Zhang H, Yan G; Multi-Center Registry of EXCEL BiodegrAdable Polymer Drug EluTing Stents (CREATE) investigators. Han Y, et al. Catheter Cardiovasc Interv. 2012 Feb 1;79(2):211-6. doi: 10.1002/ccd.23113. Epub 2011 Nov 30. Catheter Cardiovasc Interv. 2012. PMID: 21523893 Clinical Trial.
Comparison of double kissing crush versus Culotte stenting for unprotected distal left main bifurcation lesions: results from a multicenter, randomized, prospective DKCRUSH-III study.
Chen SL, Xu B, Han YL, Sheiban I, Zhang JJ, Ye F, Kwan TW, Paiboon C, Zhou YJ, Lv SZ, Dangas GD, Xu YW, Wen SY, Hong L, Zhang RY, Wang HC, Jiang TM, Wang Y, Chen F, Yuan ZY, Li WM, Leon MB. Chen SL, et al. Among authors: han yl. J Am Coll Cardiol. 2013 Apr 9;61(14):1482-8. doi: 10.1016/j.jacc.2013.01.023. Epub 2013 Mar 10. J Am Coll Cardiol. 2013. PMID: 23490040 Free article. Clinical Trial.
A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL, Xu B, Lansky AJ, Yang YJ, Ma CS, Han YL, Chen SL, Li H, Zhang RY, Fu GS, Yuan ZY, Jiang H, Huo Y, Li W, Zhang YJ, Leon MB; TARGET I Investigators. Gao RL, et al. Among authors: han yl. EuroIntervention. 2013 May 20;9(1):75-83. doi: 10.4244/EIJV9I1A12. EuroIntervention. 2013. PMID: 23685298 Free article. Clinical Trial.
The anatomic- and clinical-based NERS (new risk stratification) score II to predict clinical outcomes after stenting unprotected left main coronary artery disease: results from a multicenter, prospective, registry study.
Chen SL, Han YL, Zhang YJ, Ye F, Liu HW, Zhang JJ, Xu B, Jiang TM, Zhou YJ, Lv SZ. Chen SL, et al. Among authors: han yl. JACC Cardiovasc Interv. 2013 Dec;6(12):1233-41. doi: 10.1016/j.jcin.2013.08.006. Epub 2013 Nov 13. JACC Cardiovasc Interv. 2013. PMID: 24239199 Free article.
A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial.
Xu B, Gao R, Wang J, Yang Y, Chen S, Liu B, Chen F, Li Z, Han Y, Fu G, Zhao Y, Ge J; PEPCAD China ISR Trial Investigators. Xu B, et al. JACC Cardiovasc Interv. 2014 Feb;7(2):204-211. doi: 10.1016/j.jcin.2013.08.011. JACC Cardiovasc Interv. 2014. PMID: 24556098 Free article. Clinical Trial.
Impact of the complexity of bifurcation lesions treated with drug-eluting stents: the DEFINITION study (Definitions and impact of complEx biFurcation lesIons on clinical outcomes after percutaNeous coronary IntervenTIOn using drug-eluting steNts).
Chen SL, Sheiban I, Xu B, Jepson N, Paiboon C, Zhang JJ, Ye F, Sansoto T, Kwan TW, Lee M, Han YL, Lv SZ, Wen SY, Zhang Q, Wang HC, Jiang TM, Wang Y, Chen LL, Tian NL, Cao F, Qiu CG, Zhang YJ, Leon MB. Chen SL, et al. Among authors: han yl. JACC Cardiovasc Interv. 2014 Nov;7(11):1266-76. doi: 10.1016/j.jcin.2014.04.026. Epub 2014 Oct 15. JACC Cardiovasc Interv. 2014. PMID: 25326748 Free article.
566 results